中医药防治分子靶向治疗药物相关不良反应的研究进展
|
摘要
分子靶向治疗药物使恶性肿瘤的治疗进入一个新的时代,但相关的不良反应严重影响患者生活质量,导致靶向治疗药物减量或中断,降低抗肿瘤疗效。采用中医药防治靶向药物相关皮疹、手足皮肤反应、腹泻、周围神经病变等,取得了良好的疗效。检索中国期刊全文数据库、万方数据库及Pubmed中关于中药干预靶向药物相关不良反应的临床研究报道,并进行系统综述。
Target agents provide new treatment for malignant tumors. However,target agents related adverse events( AEs) can have a negative impact on the patient's quality of life( QOL),leading to dose modifications or drug discontinuation and compromising clinical outcome. Traditional Chinese Medicine( TCM) produced a benefit in prevention and treatment of these AEs. Clinical studies were identified by literature searches in China National Knowledge Infrastructure( CNKI) database,Wan-Fang Database and Pub Med database and a systematic review of TCM for target agents related AEs was produced.
Target agents provide new treatment for malignant tumors. However,target agents related adverse events( AEs) can have a negative impact on the patient's quality of life( QOL),leading to dose modifications or drug discontinuation and compromising clinical outcome. Traditional Chinese Medicine( TCM) produced a benefit in prevention and treatment of these AEs. Clinical studies were identified by literature searches in China National Knowledge Infrastructure( CNKI) database,Wan-Fang Database and Pub Med database and a systematic review of TCM for target agents related AEs was produced.
引文
[1]Lynch TJ Jr,Kim ES,Eaby B,et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:an evolving paradigm in clinical management[J].Oncologist,2007,12(5):610-621.
[2]Hirsh V.Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer[J].Curr Oncol,2011,18(3):126-138.
[3]Rosell R,Carcereny E,Gervais R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncol,2012,13(3):239-246.
[4]Inoue A,Kobayashi K,Maemondo M,et al.Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations(NEJ002)[J].Ann Oncol,2013,24(1):54-59.
[5]Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010,362(25):2380-2388.
[6]Gelmon KA,Boyle FM,Kaufman B,et al.Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer:Final Results of NCIC CTG MA.31[J].J Clin Oncol,2015,33(14):1574-1583.
[7]Yang X,Pan X,Cheng X,et al.Risk of Gastrointestinal Events During Lapatinib Therapy:A Meta-Analysis From 12,402 Patients With Cancer[J].Am J Ther,2016 Feb 1.
[8]Ahn JS,Lee KH,Sun JM,et al.A randomized,phase Ⅱ study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy[J].Lung Cancer,2013,82(3):455-460.
[9]Chau NG,Haddad RI.Vandetanib for the treatment of medullary thyroid cancer[J].Clinical Cancer Research,2013,19(3):524-529.
[10]Morabito A,Piccirillo MC,Falasconi F,et al.,Vandetanib(ZD6474),a dual inhibitor of vascular endothelial growth factor receptor(VEGFR)and epidermal growth factor receptor(EGFR)tyrosine kinases:current status and future directions[J].the Oncologist,2009,14(4):378-390.
[11]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label,randomized phase 3trial[J].Lancet Oncol,2014,15(2):213-222.
[12]Holcmann M,Sibilia M.Mechanisms underlying skin disorders induced by EGFR inhibitors[J].Mol Cell Oncol,2015,2(4):e1004969.
[13]Takata T,Tarutani M,Zouboulis CC,et al.Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption[J].J Dermatol Sci,2012,66(2):165-168.
[14]Belum VR,Benhuri B,Postow MA,et al.Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor[J].Eur J Cance,2016,31(60):12-25.
[15]Eigentler TK,Hassel JC,Berking C,et al.Diagnosis,monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J].Cancer Treat Rev,2016,45:7-18.
[16]王红岩,邹超,崔慧娟,等.外用清热利湿中药治疗表皮生长因子受体拮抗剂相关皮疹120例临床研究[J].北京中医药大学学报:中医临床版,2013,20(4):14-17.
[17]王红岩,邹超,崔慧娟,等.止痒平肤液治疗表皮生长因子受体拮抗剂相关皮肤不良反应的疗效观察[J].中国中西医结合杂志,2015,35(7):820-822.
[18]梁翠微,杨兵,杜均祥,等.吉非替尼相关皮疹的中医辨证论治[J].中国实用医药,2011,6(16):28-29.
[19]袁国荣,潘智敏.沙参麦门冬汤减轻易瑞沙不良反应的临床研究[J].中华中医药学刊,2011,29(4):930-932.
[20]陈端洪.加味枇杷清肺饮治疗EGFR-TKI致皮疹的临床观察[D].哈尔滨:黑龙江中医药大学,2012.
[21]邓博,贾立群,崔慧娟.中药干预表皮生长因子受体抑制剂相关皮疹的荟萃分析[J].中日友好医院学报,2016,30(1):30-35.
[22]邹超.外用中药制剂治疗EGFRIs相关皮肤干燥的临床研究[D].北京:北京中医药大学,2013.
[23]徐央波.四种外用药物治疗EGFRIs皮肤干燥的自身对照临床研究[D].北京:北京中医药大学,2015.
[24]孙韬,杨婕.肺癌靶向治疗药物毒不良反应的中西医治疗[J].北京中医药大学学报(中医临床版),2012,19(4):56-58.
[25]Garcia AA,Sill MW,Lankes HA,et al.A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma:a gynecologic oncology group study[J].Gynecol Oncol,2012,124(3):569-574.
[26]Janjigian YY.Lapatinib in Gastric Cancer:What Is the LOGiCal Next Step?[J].J Clin Oncol,2016,34(5):401-403.
[27]Ramlau R,Thomas M,Novello S,et al.Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNAas a Potential Biomarker[J].Clin Lung Cancer,2015,16(5):348-357.
[28]刘浩,侯炜,王辉,等.参一胶囊联合吉非替尼治疗晚期非小细胞肺癌50例临床研究[J].中医杂志,2012,53(11):933-935,966.
[29]张琇文,邵怿,张欣欣,等.参苓白术颗粒联合吉非替尼/厄罗替尼治疗脾气虚型晚期非小细胞肺癌临床研究[J].新中医,2014,46(1):127-129.
[30]张超,童佳兵,王彬,等.解毒消痈中药灌肠联合靶向药物治疗老年晚期非小胞肺癌的临床观察[J].陕西中医,2015,36(8):1017-1019.
[31]郦安琪,潘方舒,舒琦瑾,等.中医药联合EGFR-TKIs治疗ⅢA-Ⅳ期非小细胞肺癌的系统评价和Meta分析[J].中华中医药杂志,2016,31(2):640-644.
[32]Sheng X,Chi Z,Cui C,et al.Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma:largest single-center retrospective analysis[J].Oncotarget,2016 Feb 15.
[33]邓博,贾立群,李玲.靶向治疗药物多激酶抑制剂导致的手足皮肤反应研究进展[J].中国药学杂志,2010,45(23):94-96.
[34]Pivot X,Manikhas A,Z·urawski B,et al.CEREBEL(EGF111438):A Phase III,Randomized,Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer[J].J Clin Oncol,2015,33(14):1564-1573.
[35]Robert C,Soria JC,Spatz A,et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies[J].Lancet Oncol,2005,6(7):491-500.
[36]Lacouture ME,Wu S,Robert C,et al.Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib[J].Oncologist,2008,13(9):1001-1011.
[37]Kudo M,Ikeda M,Takayama T,et al.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice:a subgroup analysis of GIDEON[J].J Gastroenterol,2016 Apr 22.
[38]魏征,蔡小平,张俊萍.甘草泻心汤治疗索拉非尼化疗后手足皮肤反应[J].中国老年学杂志,2016,36(5):1218-1219.
[39]张晓丽,詹亚卿.金银花预防索拉菲尼肝癌患者手足皮肤反应的调查研究[J].护士进修杂志,2013,28(8):736-737.
[40]柯熹,骆惠玉,何晓华,等.芦荟胶外涂预防非小细胞肺癌靶向治疗相关性皮肤反应[J].护理学杂志,2014,29(10):15-17.
[41]蒋海华,周小平,繆景霞,等.百多邦联合新癀片治疗多吉美引起Ⅲ度手足皮肤反应的疗效观察及护理[J].现代临床护理,2012,22(9):21-22.
[42]Scott K,Hayden PJ,Will A,et al.Bortezomib for the treatment of multiple myeloma[J].Cochrane Database Syst Rev,2016(4):4.
[43]Windebank AJ,Grisold W.Chemotherapy-induced neuropathy[J].J Peripher Nerv Syst,2008,13(1):27-46.
[44]Grisold W,Cavaletti G,Windebank AJ.Peripheral neuropathies from chemotherapeutics and targeted agents:diagnosis,treatment,and prevention[J].Neuro Oncol,2012(Suppl 4):45-54.
[45]Yamamoto S,Kawashiri T,Higuchi H,et al.Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats[J].J Pharmacol Sci,2015,129(1):43-50.
[46]Staff NP,Podratz JL,Grassner L,et al.Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons[J].Neurotoxicology,2013,39:124-131.
[47]Robinson CR,Dougherty PM.Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy[J].Neuroscience,2015,285:1-10.
[48]Li ZY,Zhang YP,Zhang J,et al.The possible involvement of JNK activation in the spinal dorsal horn in bortezomib-induced allodynia:the role of TNF-αand IL-1β[J].J Anesth,2016,30(1):55-63.
[49]柯燕,莫敏敏,陈楚楚,等.经验外洗方治疗多发性骨髓瘤化疗后周围神经病变20例[J].陕西中医药大学学报,2016(1):56-58.
[50]陈楚楚,胡致平,戴铁颖.马钱子胶囊治疗硼替佐米引起周围神经病变的临床研究[J].黑龙江中医药,2015(6):20-21.
[51]许晓峰,张学进,杨国良,等.茅莓汤联合维生素B12治疗万珂引起多发性骨髓瘤周围神经病变的临床研究[J].中国中医药科技,2012(1):13-14.
[52]姚铁柱,徐志宏,马景涛,等.心脉隆注射液对曲妥珠单抗和蒽环类药物序贯化疗乳腺癌患者致心脏毒性气虚血瘀证的保护作用[J].中国实验方剂学杂志,2016,22(6):154-158.
[2]Hirsh V.Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer[J].Curr Oncol,2011,18(3):126-138.
[3]Rosell R,Carcereny E,Gervais R,et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomised phase 3 trial[J].Lancet Oncol,2012,13(3):239-246.
[4]Inoue A,Kobayashi K,Maemondo M,et al.Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations(NEJ002)[J].Ann Oncol,2013,24(1):54-59.
[5]Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010,362(25):2380-2388.
[6]Gelmon KA,Boyle FM,Kaufman B,et al.Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer:Final Results of NCIC CTG MA.31[J].J Clin Oncol,2015,33(14):1574-1583.
[7]Yang X,Pan X,Cheng X,et al.Risk of Gastrointestinal Events During Lapatinib Therapy:A Meta-Analysis From 12,402 Patients With Cancer[J].Am J Ther,2016 Feb 1.
[8]Ahn JS,Lee KH,Sun JM,et al.A randomized,phase Ⅱ study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy[J].Lung Cancer,2013,82(3):455-460.
[9]Chau NG,Haddad RI.Vandetanib for the treatment of medullary thyroid cancer[J].Clinical Cancer Research,2013,19(3):524-529.
[10]Morabito A,Piccirillo MC,Falasconi F,et al.,Vandetanib(ZD6474),a dual inhibitor of vascular endothelial growth factor receptor(VEGFR)and epidermal growth factor receptor(EGFR)tyrosine kinases:current status and future directions[J].the Oncologist,2009,14(4):378-390.
[11]Wu YL,Zhou C,Hu CP,et al.Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6):an open-label,randomized phase 3trial[J].Lancet Oncol,2014,15(2):213-222.
[12]Holcmann M,Sibilia M.Mechanisms underlying skin disorders induced by EGFR inhibitors[J].Mol Cell Oncol,2015,2(4):e1004969.
[13]Takata T,Tarutani M,Zouboulis CC,et al.Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption[J].J Dermatol Sci,2012,66(2):165-168.
[14]Belum VR,Benhuri B,Postow MA,et al.Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor[J].Eur J Cance,2016,31(60):12-25.
[15]Eigentler TK,Hassel JC,Berking C,et al.Diagnosis,monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J].Cancer Treat Rev,2016,45:7-18.
[16]王红岩,邹超,崔慧娟,等.外用清热利湿中药治疗表皮生长因子受体拮抗剂相关皮疹120例临床研究[J].北京中医药大学学报:中医临床版,2013,20(4):14-17.
[17]王红岩,邹超,崔慧娟,等.止痒平肤液治疗表皮生长因子受体拮抗剂相关皮肤不良反应的疗效观察[J].中国中西医结合杂志,2015,35(7):820-822.
[18]梁翠微,杨兵,杜均祥,等.吉非替尼相关皮疹的中医辨证论治[J].中国实用医药,2011,6(16):28-29.
[19]袁国荣,潘智敏.沙参麦门冬汤减轻易瑞沙不良反应的临床研究[J].中华中医药学刊,2011,29(4):930-932.
[20]陈端洪.加味枇杷清肺饮治疗EGFR-TKI致皮疹的临床观察[D].哈尔滨:黑龙江中医药大学,2012.
[21]邓博,贾立群,崔慧娟.中药干预表皮生长因子受体抑制剂相关皮疹的荟萃分析[J].中日友好医院学报,2016,30(1):30-35.
[22]邹超.外用中药制剂治疗EGFRIs相关皮肤干燥的临床研究[D].北京:北京中医药大学,2013.
[23]徐央波.四种外用药物治疗EGFRIs皮肤干燥的自身对照临床研究[D].北京:北京中医药大学,2015.
[24]孙韬,杨婕.肺癌靶向治疗药物毒不良反应的中西医治疗[J].北京中医药大学学报(中医临床版),2012,19(4):56-58.
[25]Garcia AA,Sill MW,Lankes HA,et al.A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma:a gynecologic oncology group study[J].Gynecol Oncol,2012,124(3):569-574.
[26]Janjigian YY.Lapatinib in Gastric Cancer:What Is the LOGiCal Next Step?[J].J Clin Oncol,2016,34(5):401-403.
[27]Ramlau R,Thomas M,Novello S,et al.Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNAas a Potential Biomarker[J].Clin Lung Cancer,2015,16(5):348-357.
[28]刘浩,侯炜,王辉,等.参一胶囊联合吉非替尼治疗晚期非小细胞肺癌50例临床研究[J].中医杂志,2012,53(11):933-935,966.
[29]张琇文,邵怿,张欣欣,等.参苓白术颗粒联合吉非替尼/厄罗替尼治疗脾气虚型晚期非小细胞肺癌临床研究[J].新中医,2014,46(1):127-129.
[30]张超,童佳兵,王彬,等.解毒消痈中药灌肠联合靶向药物治疗老年晚期非小胞肺癌的临床观察[J].陕西中医,2015,36(8):1017-1019.
[31]郦安琪,潘方舒,舒琦瑾,等.中医药联合EGFR-TKIs治疗ⅢA-Ⅳ期非小细胞肺癌的系统评价和Meta分析[J].中华中医药杂志,2016,31(2):640-644.
[32]Sheng X,Chi Z,Cui C,et al.Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma:largest single-center retrospective analysis[J].Oncotarget,2016 Feb 15.
[33]邓博,贾立群,李玲.靶向治疗药物多激酶抑制剂导致的手足皮肤反应研究进展[J].中国药学杂志,2010,45(23):94-96.
[34]Pivot X,Manikhas A,Z·urawski B,et al.CEREBEL(EGF111438):A Phase III,Randomized,Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer[J].J Clin Oncol,2015,33(14):1564-1573.
[35]Robert C,Soria JC,Spatz A,et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies[J].Lancet Oncol,2005,6(7):491-500.
[36]Lacouture ME,Wu S,Robert C,et al.Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib[J].Oncologist,2008,13(9):1001-1011.
[37]Kudo M,Ikeda M,Takayama T,et al.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice:a subgroup analysis of GIDEON[J].J Gastroenterol,2016 Apr 22.
[38]魏征,蔡小平,张俊萍.甘草泻心汤治疗索拉非尼化疗后手足皮肤反应[J].中国老年学杂志,2016,36(5):1218-1219.
[39]张晓丽,詹亚卿.金银花预防索拉菲尼肝癌患者手足皮肤反应的调查研究[J].护士进修杂志,2013,28(8):736-737.
[40]柯熹,骆惠玉,何晓华,等.芦荟胶外涂预防非小细胞肺癌靶向治疗相关性皮肤反应[J].护理学杂志,2014,29(10):15-17.
[41]蒋海华,周小平,繆景霞,等.百多邦联合新癀片治疗多吉美引起Ⅲ度手足皮肤反应的疗效观察及护理[J].现代临床护理,2012,22(9):21-22.
[42]Scott K,Hayden PJ,Will A,et al.Bortezomib for the treatment of multiple myeloma[J].Cochrane Database Syst Rev,2016(4):4.
[43]Windebank AJ,Grisold W.Chemotherapy-induced neuropathy[J].J Peripher Nerv Syst,2008,13(1):27-46.
[44]Grisold W,Cavaletti G,Windebank AJ.Peripheral neuropathies from chemotherapeutics and targeted agents:diagnosis,treatment,and prevention[J].Neuro Oncol,2012(Suppl 4):45-54.
[45]Yamamoto S,Kawashiri T,Higuchi H,et al.Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats[J].J Pharmacol Sci,2015,129(1):43-50.
[46]Staff NP,Podratz JL,Grassner L,et al.Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons[J].Neurotoxicology,2013,39:124-131.
[47]Robinson CR,Dougherty PM.Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy[J].Neuroscience,2015,285:1-10.
[48]Li ZY,Zhang YP,Zhang J,et al.The possible involvement of JNK activation in the spinal dorsal horn in bortezomib-induced allodynia:the role of TNF-αand IL-1β[J].J Anesth,2016,30(1):55-63.
[49]柯燕,莫敏敏,陈楚楚,等.经验外洗方治疗多发性骨髓瘤化疗后周围神经病变20例[J].陕西中医药大学学报,2016(1):56-58.
[50]陈楚楚,胡致平,戴铁颖.马钱子胶囊治疗硼替佐米引起周围神经病变的临床研究[J].黑龙江中医药,2015(6):20-21.
[51]许晓峰,张学进,杨国良,等.茅莓汤联合维生素B12治疗万珂引起多发性骨髓瘤周围神经病变的临床研究[J].中国中医药科技,2012(1):13-14.
[52]姚铁柱,徐志宏,马景涛,等.心脉隆注射液对曲妥珠单抗和蒽环类药物序贯化疗乳腺癌患者致心脏毒性气虚血瘀证的保护作用[J].中国实验方剂学杂志,2016,22(6):154-158.